• 1
    Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol. 1988; 128: 467477.
  • 2
    Wang J, Costantino JP, Tan-Chiu E, Wickerham DL, Paik S, Wolmark N. Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst. 2004; 96: 616620.
  • 3
    Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985; 55: 26982708.
  • 4
    London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992; 267: 941944.
  • 5
    Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer. 1996; 78: 10241034.
  • 6
    Hutchinson WB, Thomas DB, Hamlin WB, Roth GJ, Peterson AV, Williams B. Risk of breast cancer in women with benign breast disease. J Natl Cancer Inst. 1980; 65: 1320.
  • 7
    Roberts MM, Jones V, Elton RA, Fortt RW, Williams S, Gravelle IH. Risk of breast cancer in women with history of benign disease of the breast. Br Med J (Clin Res Ed). 1984; 288: 275278.
  • 8
    Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005; 353: 229237.
  • 9
    Page DL, Kidd TEJr., Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991; 22: 12321239.
  • 10
    Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997; 6: 297301.
  • 11
    Sloane JP, Anderson T, Davies J, et al. Pathology reporting in breast cancer screening: national coordinating group for breast screening pathology. Sheffield, UK: NHSBSP Publications, 1995.
  • 12
    Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement.Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med. 1998; 122: 10531055.
  • 13
    Simpson JF, Page DL. Lobular neoplasia: atypical lobular neoplasia and lobular carcinoma in situ. In: ElstonCW, editor. The breast. Edinburgh: Churchill Livingstone, 1998: 91106.
  • 14
    McDivitt RW SJ, Lee NC. Histologic types of benign breast disease and the risk of breast cancer. The Cancer and Steroid Hormone Study Group. Cancer. 1992; 69: 14081414.
  • 15
    Page DL, Dupont WD, Rogers LW. Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk. Hum Pathol. 1988; 19: 201207.
  • 16
    Lambird PA, Shelley WM. The spatial distribution of lobular in situ mammary carcinoma. Implications for size and site of breast biopsy. JAMA. 1969; 210: 689693.
  • 17
    Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WDJr., Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003; 361: 125129.
  • 18
    Rosen PP, Braun DWJr., Lyngholm B, Urban JA, Kinne DW. Lobular carcinoma in situ of the breast: preliminary results of treatment by ipsilateral mastectomy and contralateral breast biopsy. Cancer. 1981; 47: 813819.
  • 19
    Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004; 100: 238244.
  • 20
    Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of Surveillance, Epidemiology, and End Results data. J Clin Oncol. 2005; 23: 55345541.
  • 21
    Andersen J. Lobular carcinoma in situ. A long-term follow-up in 52 cases. Acta Pathol Scand [A]. 1974; 82: 519533.
  • 22
    Page DL. Special types of invasive breast cancer, with clinical implications. Am J Surg Pathol. 2003; 27: 832835.
  • 23
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403410.
  • 24
    Schnitt SJ. Pathology of invasive breast cancer. In: HarrisJL, MorrowM, OsborneCK, editors. Diseases of the breast. Philadelphia: Lippincott, Williams & Wilkins, 2004: 541584.
  • 25
    Page DL, Anderson TJ. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987.
  • 26
    Dupont WD. Statistical modeling for biomedical researchers: a simple introduction to the analysis of complex data. Cambridge, UK: Cambridge University Press, 2002.
  • 27
    Hoel P. Introduction to mathematical statistics. New York: John Wiley & Sons, 1984.
  • 28
    Stata Statistical Software: Release 8.0 College Station, TX: Stata, 2003.
  • 29
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER *Stat Database: Mortality—all COD, public-use with state, total U.S. for expanded races/Hispanics (1990–2002). Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2005.
  • 30
    Page DL, Simpson JF. What is atypical lobular hyperplasia and what does it mean for the patient? J Clin Oncol. 2005; 23: 54325433.
  • 31
    Dixon JM, Page DL, Anderson TJ, et al. Long-term survivors after breast cancer. Br J Surg. 1985; 72: 445448.
  • 32
    Page DL, Jensen RA, Simpson JF. Premalignant and malignant disease of the breast: the roles of the pathologist. Mod Pathol. 1998; 11: 120128.
  • 33
    Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992; 20: 479489.
  • 34
    Fitzgibbons PL, Page DL, Weaver DD, et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124: 966978.
  • 35
    Wood WC, Styblo T. Clinically established prognostic factors in breast cancer, 3rd ed., vol. 1. St. Louis: WB Saunders, 2004.
  • 36
    Bloom HJ, Richardson WW, Field JR. Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years. Br Med J. 1970; 3: 181188.
  • 37
    Brinton LA, Persson I, Boice JDJr., McLaughlin JK, Fraumeni JFJr. Breast cancer risk in relation to amount of tissue removed during breast reduction operations in Sweden. Cancer. 2001; 91: 478483.
  • 38
    Beller FK, Nitsch CD, Nienhaus H. Treatment aspects of minimal breast cancer. Recent Results Cancer Res. 1988; 106: 7384.
  • 39
    Freeman BS, Wiemer DR. Total glandular mastectomy. Modifications of the subcutaneous mastectomy for use in premalignant disease of the breast. Plast Reconstr Surg. 1978; 62: 167172.
  • 40
    Barton FEJr., English JM, Kingsley WB, Fietz M. Glandular excision in total glandular mastectomy and modified radical mastectomy: a comparison. Plast Reconstr Surg. 1991; 88: 389392; discussion 93–94.
  • 41
    Newman LA, Kuerer HM, Hung KK, et al. Prophylactic mastectomy. J Am Coll Surg. 2000; 191: 322330.
  • 42
    Goffman TE, Schneider H, Hay K, Elkins DE, Schnarrs RA, Carman C. Cosmesis with bilateral mammoreduction for conservative breast cancer treatment. Breast J. 2005; 11: 195198.
  • 43
    Hutter RV, Foote FWJr. Lobular carcinoma in situ. Long term follow-up. Cancer. 1969; 24: 10811085.